|
|
Volumn 53, Issue 1, 2012, Pages 165-
|
|
18F-FDG PET/CT as a sensitive and early treatment monitoring tool: Will this become the major thrust for its clinical application in infectious and inflammatory disorders?
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ETHAMBUTOL;
FLUORODEOXYGLUCOSE F 18;
ISONIAZID;
PYRAZINAMIDE;
RIFAMPICIN;
STREPTOMYCIN;
DIAGNOSTIC AGENT;
RADIOPHARMACEUTICAL AGENT;
TUBERCULOSTATIC AGENT;
ALTERNATIVE MEDICINE;
CLINICAL PRACTICE;
COMPUTER ASSISTED EMISSION TOMOGRAPHY;
DIFFERENTIAL DIAGNOSIS;
DRUG EFFICACY;
DRUG MONITORING;
DRUG RESISTANT TUBERCULOSIS;
DRUG TREATMENT FAILURE;
DRUG UPTAKE;
EARLY INTERVENTION;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT;
INFECTION;
INFLAMMATORY DISEASE;
LETTER;
MOLECULAR IMAGING;
MULTIDRUG RESISTANT TUBERCULOSIS;
PATIENT SELECTION;
PREDICTIVE VALUE;
PRIORITY JOURNAL;
RELIABILITY;
SARCOIDOSIS;
SENSITIVITY ANALYSIS;
SENSITIVITY AND SPECIFICITY;
STEROID THERAPY;
TREATMENT DURATION;
TREATMENT OUTCOME;
TREATMENT RESPONSE;
TUBERCULOSIS;
VASCULITIS;
AIDS RELATED COMPLEX;
FEMALE;
MALE;
NOTE;
SCINTISCANNING;
AIDS-RELATED OPPORTUNISTIC INFECTIONS;
ANTITUBERCULAR AGENTS;
FEMALE;
FLUORODEOXYGLUCOSE F18;
HUMANS;
MALE;
RADIOPHARMACEUTICALS;
TUBERCULOSIS;
|
|
EID: 84855368017
PISSN: 01615505
EISSN: None
Source Type: Journal
DOI: 10.2967/jnumed.111.095026 Document Type: Letter |
|
Times cited : (7)
|
|
References (3)
|
